11 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancerRecruitingPhase 22026-10-09NCT06401980
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinomaActive, not recruitingPhase 32026-09-08NCT07005128
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerBites and Stings, Chemically-Induced Disorders, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, injury, male reproductive organ cancer, male reproductive system disorder, neoplasm, poisoning, prostate cancer, prostate disorderRecruitingPhase 12026-08-21NCT04221542
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderRecruitingPhase 12026-07-02NCT07140900
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinomaRecruitingPhase 12026-06-26NCT06598306
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck CancerOligometastatic Squamous Cell Carcinoma of the Head and NeckRecruitingPhase 32026-05-28NCT05815927
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderActive, not recruitingPhase 32026-05-15NCT06691984
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBCFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorderActive, not recruitingPhase 22026-01-21NCT04630730
Reduced Intensity Radio-chemotherapy for Stage IIA/B SeminomaGenital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, germinoma, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, seminoma, testicular cancer, testicular disorderActive, not recruitingPhase 22026-01-20NCT03937843
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinomaActive, not recruitingPhase 32026-01-05NCT05740566
Prostate Cancer BiobankGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderActive, not recruitingNot stated2022-06-08NCT04024475